Buscar
Mostrando ítems 1-1 de 1
Artículo
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238
(American Association Cancer Research, 2023)
lumab significantly improved recurrence-free survival (RFS) and distant metastasis-free survival versus ipilimumab in patients with resected stage IIIB–C or stage IVmelanoma,with benefit sustained at 4 years. We report ...